rais bar
report increas convict compani
connect care strategi continu drive market share
gain higher rate high-margin resuppli sale
ow long durat growth support larg instal base growth ii
sale iv on-going oper leverag near term see two headwind
row devic segment growth low cycl period benefit
favor reimburs chang ii ep dilut verili propel
point report global mask sale acceler
constant fx outpac global devic sale contribut
higher gm vs pcp ii row devic constant fx weaker
expect hinder favor reimburs chang
compar period iii ep dilut invest broadli line
differ see less gm pressur past year
us reimburs stabl least jan though watch
news flow regard new us competit bid rate ii upsid
penetr copd market via portabl oxygen concentr
propel long term iii recoveri row devic
high growth period lap concomit higher resuppli sale
softwar invest underpin long-term growth expertis patient
connect within osa ecosystem born fruit patient complianc
improv resuppli move higher demonstr us mask/oth
revenu growth highest growth sinc deliv
propel health near-term dilut may open copd market
lead downstream referr inhal patient poc/vent diseas
progress clinic trial novarti announc
valuat sit vs coverag trade ep remain
ow still prefer stock australian off-shore growth earner
ow-rat ew-rat ep
up/downsid price target
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
exhibit statist resm cdi
price target convert cdi
cdi disclaim end report morgan stanley research
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
wide dispers outcom exist
wide dispers outcom exist
us devic growth higher current forecast addit small move
mask turn see upsid poc reach share
appli dcf valuat forecast includ step us
growth rate associ new product launch decay pa long
bear case assum reduct us mask price reduct us unit
growth remain intern level pa poc remain
rate ow market share gain
increas instal base support
futur posit momentum sale
consum enhanc confid
long-term sustain ep growth
product launch without rmd
top line would revert market growth rate
fewer price declin pa
weather cost increas line cpi
growth rate possibl owe
under-penetr osa suffer co-
high growth high-margin
therapi repeat mask/dispos sale
occur
upsid at-hom diagnosi de-
bottleneck clinic pathway
data uptak competitor next-
traction upcom launch three new
exhibit bear bull device/mask asp gm biggest valu driver
mask turn
mask turn asp pressur
gm next
risk achiev price
advers impact us competit bid
loss cpap market share
eur usd continu deterior
result review
global mask cc said achiev market growth took market
share support new mask mask beat mse
global devic cc devic us row cc said
strong growth achiev uk switzerland nordic countri off-set
on-going headwind devic growth franc expect return normal
growth rate franc end
saa segment line mse said underli market growth
saa market hsd expect exit solid double-digit growth
segment
ep beat overal achiev revenu growth ahead
mse ep grew ahead mse
gp margin expand mse guid
sale sale balanc year
compani data morgan stanley research estim mse account verili cost pre-tax profit number adjust show like-for-lik basi
chang forecast
global mask sale increas forecast year follow stronger
expect sale
lower us devic sale due lower base
saa revenu came expect led low singl digit
upgrad forecast year
increas gross profit margin
small chang ep driven chang forecast
exhibit chang estim follow
compani data morgan stanley research account verili cost pre-tax profit number adjust show like-for-lik basi
deriv price target use blend bull base bear case
base case weight use longer-term-depend dcf
valuat methodolog use wacc growth rate
bull case weight
bear case weight
downsid risk price target includ
advers impact us competit bid
continu loss cpap market share
eur usd continu deterior
base case valuat increas driven posit ep
price target rise driven higher valuat
base bull bear case
assumpt base case dcf valuat summar
debt
equiti
npv cashflow
valu equiti
share issu
price target convert cdi
investor awar calcul take account
issu risk associ invest adr includ limit
liquid vote right dividend volatil currenc exchang rate
cdi base case move due higher rmd base
profit loss
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
 fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
note provid research coverag list cdi associ underli ordinari share compani courtesi may includ cdi price target cdi share price aud
dollar research report unless otherwis state cdi price target convers calcul use appropri currenc exchang rate ordinari share versu cdi ratio investor awar
calcul take account issu risk associ invest cdi includ limit liquid vote right dividend volatil currenc exchang rate fluctuat
price target deriv blend bull base bear case
base case weight valu use dcf wacc assum
wacc termin growth rate
bull case weight
bear case weight
downsid risk achiev price target lower-than-expect adopt next-
gener rcoag product appreci aud usd chang us
price target coh ax deriv use blend bull base bear
base case weight base-cas scenario dcf assum
wacc termin growth rate
bull case weight
bear case weight
risk achiev price target
upsid faster roll-out nucleu profil weaken higher
penetr upgrad market
downsid reimburs restrict us develop eu strengthen
disappoint uptak new product
